case_images: PMC10996918_01
case_images: (A,B) FLAIR sequence in axial plane at two different levels; hyperintense demyelinating lesions (A) periventricular, above the left lateral ventricle (arrow), (B) in the deep white matter of the right centrum semiovale (arrow); (C) T1 contrast enhancement sequence in axial plane; homogeneous contrast enhancement of an active lesion (arrow).
case_images: fneur-15-1359938-g001.jpg
case_images: PMC10996918_01_fneur-15-1359938-g001.jpg
case_images: fig1
case_images: All of them displayed gadolinium enhancement (Figure 1).
case_images: PMC10996918_02
case_images: PMC10996918_03
case_images: Follow-up MRI after 1 year: FLAIR sequence in axial plane at three different levels (A-C); progression of the disease; multiple demyelinating lesions in typical periventricular (arrows) and juxtacortical locations (arrowheads). Among the periventricular lesions, we can observe a lesion in the splenium of the corpus callosum on the left side (thick arrow). Other new lesions can also be observed in the subcortical and deep white matter of the frontoparietal lobes. The lesions shown in Figure 1 have partially regressed (black arrows).
case_images: fneur-15-1359938-g002.jpg
case_images: PMC10996918_03_fneur-15-1359938-g002.jpg
case_images: fig2
case_images: A brain and spinal cord MRI revealed 5 new lesions, two of them displayed gadolinium enhancing (Figure 2).
case_images: PMC10996918_04
case_images: Follow-up MRI after 2 years: FLAIR sequence in axial plane at the same levels as in Figure 2
  (A-C); Partial regression of demyelinating lesions after initiation of therapy.
case_images: fneur-15-1359938-g003.jpg
case_images: PMC10996918_04_fneur-15-1359938-g003.jpg
case_images: fig3
case_images: A follow-up MRI 6 months after rituximab administration showed regression of the multiple demyelinating lesions and no new lesions (Figure 3).
case_images: PMC10996918_05
case_images: Case timeline.
case_images: fneur-15-1359938-g004.jpg
case_images: PMC10996918_05_fneur-15-1359938-g004.jpg
case_images: fig4
case_images: He had already received three doses of rituximab and had not relapsed after starting this therapy (Figure 4).
case_images: PMC10996918_06